# SAFETY DATA SHEET



# SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation

**GAVISCON TABLETS** 

of the mixture

Registration number

**Synonyms** ALGINIC ACID 200 MG AND ALUMINUM HYDROXIDE 80 MG CHEWABLE TABLETS \* ALGINIC

ACID, PANADOL, MAGNESIUM SILICATE, AND ALUMINUM HYDROXIDE, FORMULATED

**PRODUCT** 

18-November-1998 Issue date

Version number 13

**Revision date** 27-April-2012 Supersedes date 19-April-2012

# 1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses Medicinal Product

> This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant

to medicinal use of the product. In this instance patients should consult prescribing

information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate

safety data sheet for each ingredient.

Uses advised against No other uses are advised.

### 1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK 980 Great West Road

Brentford, Middlesex TW8 9GS UK

UK General Information (normal business hours): +44-20-8047-5000

Email Address: msds@gsk.com Website: www.gsk.com

1.4. Emergency telephone

number

TRANSPORT EMERGENCIES (by country / geographic region):

Africa / EU / Israel / Middle East

(English / European languages): +44 (0) 1235 239 670 Asia Pacific (except China): +65 3158 1074 China: +86 10 5100 3039 Middle East / Africa (Arabic-speaking countries): +44 (0) 1235 239 671 **United States:** +1 703 527 3887

available 24 hrs/7 days; multi-language response

# **SECTION 2: Hazards identification**

# 2.1. Classification of the substance or mixture

## Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

## Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

### 2.2. Label elements

## Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Supplemental label information Not applicable.

2.3. Other hazards Expected to be non-combustible.

Handling this product in its final form presents minimal risk from occupational exposure.

Health effects information is based on hazards of components.

No information is available about the potential of this product to produce adverse environmental

effects.

Material name: GAVISCON TABLETS SDS UK 1/7

# **SECTION 3: Composition/information on ingredients**

### 3.1. Mixtures

**General information** 

CAS-No. / EC No. REACH Registration No. Chemical name % INDEX No. **Notes** 

ALGINIC ACID 9005-32-7 12.5

232-680-1

Classification: DSD: -

CLP: -

ALUMINUM HYDROXIDE DRIED 5 Unassigned

GEL, F-2200

Classification: DSD: Xi;R36

CLP: Eye Irrit. 2;H319

**PARACETAMOL** 1.26 103-90-2

203-157-5

Classification: **DSD:** Xn;R22, N;R51/53

CLP: Acute Tox. 4;H302, Aquatic Chronic 2;H411

MAGNESIUM SILICATE 1.25 14987-04-3

239-076-7

Classification: DSD: -

CLP:

Components below reportable levels >79.0

## **SECTION 4: First aid measures**

**General information** Pre-placement and periodic health surveillance is not usually indicated. The final determination of

the need for health surveillance should be determined by local risk assessment.

4.1. Description of first aid measures

Inhalation Physical form suggests that risk of inhalation exposure is negligible.

Skin contact Using appropriate personal protective equipment, remove contaminated clothing and flush

exposed area with large amounts of water. Obtain medical attention if skin reaction occurs, which

may be immediate or delayed.

Eye contact Wash immediately with clean and gently flowing water. Continue for at least 15 minutes. Obtain

medical attention.

Ingestion Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the

exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.

4.2. Most important symptoms and effects, both acute and

delayed

None known.

4.3. Indication of any immediate medical attention and special treatment needed No specific antidotes are recommended. Treat according to locally accepted protocols. For

additional guidance, refer to the local poison control information centre.

# SECTION 5: Firefighting measures

General fire hazards Expected to be non-combustible.

5.1. Extinguishing media

Suitable extinguishing

media

Water or foam extinguishers are recommended.

Unsuitable extinguishing

Material name: GAVISCON TABLETS

media

Carbon dioxide or dry powder extinguishers may be ineffective.

5.2. Special hazards arising from the substance or mixture Toxic, corrosive or flammable thermal decomposition products are expected when the product is

exposed to fire.

5.3. Advice for firefighters

Special protective

Since toxic, corrosive or flammable vapours might be evolved from fires involving this material, equipment for firefighters

self contained breathing apparatus and full protective equipment are recommended for

firefighters.

Special fire fighting

procedures

For single units (packages): No special requirements needed.

For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapours might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters.

If possible, contain and collect firefighting water for later disposal.

# **SECTION 6: Accidental release measures**

## 6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

Wear protective clothing and equipment consistent with the degree of hazard.

For emergency responders

Use personal protection recommended in Section 8 of the MSDS.

6.2. Environmental precautions

For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage

6.3. Methods and material for containment and cleaning up

Collect and place it in a suitable, properly labelled container for recovery or disposal. No specific

decontamination or detoxification procedures have been identified for this product.

6.4. Reference to other

sections

For personal protection, see section 8. For waste disposal, see section 13.

# **SECTION 7: Handling and storage**

7.1. Precautions for safe

handling

Avoid breaking or crushing tablets.

7.2. Conditions for safe storage, including any incompatibilities

No storage requirements necessary for occupational hazards. Follow product information storage

instructions to maintain efficacy.

7.3. Specific end use(s) Medicinal Product

# **SECTION 8: Exposure controls/personal protection**

## 8.1. Control parameters

#### Occupational exposure limits

G	S	K

Components	Туре	Value		
ALGINIC ACID (9005-32-7)	OHC	1		
PARACETAMOL (103-90-2)	8 HR TWA	4000 mcg/m3		
	OHC	1		
SODIUM BICARBONATE	8 HR TWA	5000 mcg/m3	5000 mcg/m3	
(144-55-8)				
	OHC	1		
Sucrose (57-50-1)	OHC	1		
UK. EH40 Workplace Exposure Lim	nits (WELs)			
Components	Type	Value	Form	
PARACETAMOL (103-90-2)	TWA	10 mg/m3	Inhalable dust.	
United Kingdom		-		
Components	Туре	Value		
Sucrose (57-50-1)	STEL	20 mg/m3		
	TWA	10 mg/m3		

## **Biological limit values**

No biological exposure limits noted for the ingredient(s).

United Kingdom

No biological exposure limits noted for the ingredient(s).

Recommended monitoring

procedures

Not available.

**Derived No Effect Level (DNEL)** Not available. Predicted no effect

concentrations (PNECs)

Not available.

8.2. Exposure controls

Appropriate engineering

Material name: GAVISCON TABLETS

Not available.

controls

## Individual protection measures, such as personal protective equipment

**General information** An eye wash station should be available.

**Eye/face protection** Wear approved safety glasses with side shields if eye contact is possible.

Skin protection

- Hand protection None required for the normal handling of this material.

Other Not available.
 Respiratory protection Not available.
 Thermal hazards Not available.

Hygiene measures None required for normal handling. Wash hands and arms thoroughly after handling.

**Environmental exposure controls** 

Hazard guidance and Not available. control recommendations

# **SECTION 9: Physical and chemical properties**

# 9.1. Information on basic physical and chemical properties

**Appearance** 

Physical state Solid.
Form Tablet.
Colour Not available.
Odour Not available.
Odour threshold Not available.
PH Not applicable.
Melting point/freezing point Not available.
Initial boiling point and boiling Not available.

range

Flash point Not applicable.

Evaporation rate Not applicable.

Flammability (solid, gas) Not available.

Upper/lower flammability or explosive limits

Flammability limit - lower

Not available.

(%)

Flammability limit - upper

Not available.

(%)

**Explosive limit - lower (%)** Not available. **Explosive limit - upper** Not available.

(%)

Vapour pressureNot applicable.Vapour densityNot applicable.Relative densityNot available.Solubility(ies)Not available.Partition coefficientNot available.

(n-octanol/water)

Decomposition temperatureNot available.ViscosityNot applicable.Explosive propertiesNot available.Oxidizing propertiesNot available.

**9.2. Other information** No relevant additional information available.

# **SECTION 10: Stability and reactivity**

**10.1. Reactivity** Not available.

**10.2. Chemical stability**This product is expected to be stable.

10.3. Possibility of hazardous

Material name: GAVISCON TABLETS

reactions

Not available.

**10.4. Conditions to avoid**None for normal handling of this product.

**10.5. Incompatible materials** Not available.

**10.6. Hazardous** Toxic, corrosive or flammable thermal decomposition products are expected when the product is

decomposition products exposed to fire.

# **SECTION 11: Toxicological information**

**General information** Not available.

Information on likely routes of exposure

**Ingestion** Exposure from ingestion may occur. Not expected to be toxic following ingestion.

**Inhalation** Not expected to occur during normal handling of this product.

**Skin contact** Direct contact may occur. Irritation is not expected following direct contact.

**Eye contact** Direct contact may occur. Irritation is not expected following direct contact with eyes.

Symptoms Not available.

11.1. Information on toxicological effects

Acute toxicity No studies have been conducted. Not expected to be toxic following ingestion. Assessment based

upon effects of individual components.

Components Species Test results

ALGINIC ACID (9005-32-7)

Acute Oral

LD50 Rat > 5000 mg/kg

PARACETAMOL (103-90-2)

**Acute** 

Oral

LD50 Rat 1944 mg/kg

Skin corrosion/irritation No studies have been conducted. Irritation is not expected following direct contact.

Irritation Corrosion - Skin: P.I.I. value

PARACETAMOL 0.3

Serious eye damage/eye

irritation

nage/eye No studies have been conducted. Irritation is not expected following direct contact with eyes.

Assessment based upon effects of individual components.

**Respiratory sensitisation** No studies have been conducted.

Skin sensitisation Sensitisation (allergic skin reaction) is not expected. Assessment based upon effects of individual

components

**Germ cell mutagenicity**Not expected to be genotoxic, based on effects of individual components.

Carcinogenicity No studies have been conducted

IARC Monographs. Overall Evaluation of Carcinogenicity

PARACETAMOL (CAS 103-90-2) 3 Not classifiable as to carcinogenicity to humans.

Reproductive toxicity

Not expected to produce adverse effects on fertility or development under occupational exposure

conditions.

Specific target organ toxicity -

single exposure

No specific target organ effects have been identified.

Specific target organ toxicity -

repeated exposure

No specific target organ effects have been identified.

Aspiration hazard

Mixture versus substance

No studies have been conducted.

Wixture versus subsi

information

Components

No studies have been conducted.

Species

promelas)

**Other information** None known for occupational exposure.

**SECTION 12: Ecological information** 

**12.1. Toxicity**No information is available about the potential of this product to produce adverse environmental

effects. Local regulations and procedures should be consulted prior to environmental release.

**Test results** 

PARACETAMOL (103-90-2) Aquatic Acute Algae EC50 Green algae (Scenedesmus 134 mg/l, 72 hours subspicatus) Crustacea EC50 Water flea (Daphnia magna) 9.2 mg/l, 48 hours, Static test Fish EC50 Fathead minnow (Juvenile Pimephales 814 mg/l, 96 hours, Flow-through test

Material name: GAVISCON TABLETS

Components Species Test results

Microtox EC50 Microtox 1000 mg/l, 30 minutes

## 12.2. Persistence and degradability

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

PARACETAMOL 99 %, 5 days Modified Zahn-Wellens, Activated sludge

12.3. Bioaccumulative potential Not available.

Partition coefficient n-octanol/water (log Kow)

PARACETAMOL 0.36

12.4. Mobility in soil Mobility in general

Volatility

Henry's law

PARACETAMOL 0 atm m<sup>3</sup>/mol Estimated

12.5. Results of PBT

and vPvB assessment

Not available.

**12.6. Other adverse effects** Not available.

# **SECTION 13: Disposal considerations**

13.1. Waste treatment methods

Residual waste Not available.

Contaminated packaging Not available.

EU waste code Not available.

Disposal methods/information Observe all local and national regulations when disposing of this product. Collect for recycling or

recovery if possible. The disposal method for rejected products/returned goods must ensure that

they cannot be re-sold or re-used.

# **SECTION 14: Transport information**

The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorised persons trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous goods for transport.

#### **ADR**

Not regulated as dangerous goods.

#### IATA

Not regulated as dangerous goods.

### IMDG

Not regulated as dangerous goods.

## **SECTION 15: Regulatory information**

# 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

### EU regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I

Not listed.

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II

Not listed

Regulation (EC) No. 850/2004 on persistent organic pollutants, Annex I as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended

Not listed

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Not listed.

## Regulation (EC) No. 1907/2006, REACH Article 59(1) Candidate List as currently published by ECHA

Not listed.

#### **Authorisations**

Regulation (EC) No. 143/2011 Annex XIV Substances Subject to Authorisation

Not listed.

#### Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended

Not listed.

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

Not listed

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

#### Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Not listed.

National regulations Not available.

15.2. Chemical safety Not available.

assessment

#### **SECTION 16: Other information**

**List of abbreviations** Not available.

**References** GSK Hazard Determination

Information on evaluation method leading to the classification of mixture

Not available.

Full text of any statements or R-phrases and H-statements

R22 Harmful if swallowed. R36 Irritating to eyes.

under Sections 2 to 15

R51/53 Toxic to aquatic organisms, May cause long-term adverse effects in the aquatic

environment.

H302 - Harmful if swallowed. H319 - Causes serious eye irritation.

H411 - Toxic to aquatic life with long lasting effects.

Revision informationNot available.Training informationNot available.

**Disclaimer** The information and recommendations in this safety data sheet are, to the best of our knowledge,

accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and

the suitability of the material or product for any particular purpose.

**Issue date** 18-November-1998

Revision date 27-April-2012

Material name: GAVISCON TABLETS